Zika as Cancer Buster?

By infecting glioblastoma cells but not healthy brain tissue, some form of the virus could serve a therapeutic purpose.

| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

ABOVE: © ISTOCK.COM, CIPHOTOS

The paper
Z. Zhu et al., “Zika virus targets glioblastoma stem cells through a SOX2-integrin αvβ5 axis,” Cell Stem Cell, 26:187–204.E10, 2020.

In 2017, University of California, San Diego, regenerative medicine researcher Zhe Zhu and colleagues found that the Zika virus, which sparked a widespread epidemic in the Americas a few years ago and is known to cause microcephaly in fetuses by destroying neural stem cells, preferentially targets and kills glioblastoma stem cells. The researchers argued that a modified form of Zika could potentially be used as an oncolytic virus therapy against glioblastoma, an aggressive type of brain cancer.

Following up on that work, Zhu and collaborators set out to find “the unique property of this virus” that allows Zika to selectively target brain cancer stem cells while sparing adjacent tissues, says Zhu. Previous research has shown that a number of viruses use integrins, a group of ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Keywords

Meet the Author

  • Amy Schleunes

    A former intern at The Scientist, Amy studied neurobiology at Cornell University and later earned her MFA in creative writing from the University of Iowa. She is a Los Angeles–based writer, editor, and communications strategist who collaborates on nonfiction books for Harper Collins and Houghton Mifflin Harcourt, and also teaches writing at Johns Hopkins University CTY. Her favorite projects involve sharing the insights of science and medicine.

Published In

April 2020

Exercise for Cancer

Molecular clues link physical activity to improved patient outcomes

Share
May digest 2025 cover
May 2025, Issue 1

Study Confirms Safety of Genetically Modified T Cells

A long-term study of nearly 800 patients demonstrated a strong safety profile for T cells engineered with viral vectors.

View this Issue
iStock

TaqMan Probe & Assays: Unveil What's Possible Together

Thermo Fisher Logo
Meet Aunty and Tackle Protein Stability Questions in Research and Development

Meet Aunty and Tackle Protein Stability Questions in Research and Development

Unchained Labs
Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Bio-Rad
How technology makes PCR instruments easier to use.

Making Real-Time PCR More Straightforward

Thermo Fisher Logo

Products

The Scientist Placeholder Image

Biotium Launches New Phalloidin Conjugates with Extended F-actin Staining Stability for Greater Imaging Flexibility

Leica Microsystems Logo

Latest AI software simplifies image analysis and speeds up insights for scientists

BioSkryb Genomics Logo

BioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hours

iStock

Agilent BioTek Cytation C10 Confocal Imaging Reader

agilent technologies logo